Contact the team

The STOP-ACEi trial team are always here to help. For further information about the STOP-ACEi trial please contact us:

General enquiries

For general queries about the study, site set-up, collection of data and data analysis please contact the Birmingham Clinical Trials Unit.


Postal address: STOP-ACEi Trial Office
Birmingham Clinical Trials Unit (BCTU)
Institute of Applied Health Research
College of Medical and Dental Sciences
Public Health Building
University of Birmingham
B15 2TT

STOP-ACEi trial staff:

Elizabeth Brettell, Trials Manager 0121 415 9130

Marie Chadburn, Deputy Team Leader 0121 415 9133

Aisha Khan, Data Manager 0121 415 9133

Find out more information about our other renal trials and the University of Birmingham Clinical Trials Unit


The University of Birmingham Clinical Trials Unit (BCTU) is a Research Unit within the School of Medicine specialising in the design, conduct and analysis of clinical trials.


An observational study to assess the accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease: prospective longitudinal study in a multi-ethnic population.


PREDNOS 2 is a national multicentre double blind randomised controlled trial of short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome (SSNS).


Long-term tapering versus standard prednisolone (steroid) therapy for the treatment of the initial episode of childhood nephrotic syndrome: national multicentre randomised double blind trial


Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: an international randomised controlled trial.


GloMY is national, multi-centre, randomised controlled open-label pilot trial of Myfortic plus short course steroids versus standard care in patients with proteinuric primary focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).


Eculizumab in Shiga-Toxin producing E. Coli Haemolytic Uraemic Syndrome (ECUSTEC): A Randomised, Double Blind, Placebo-Controlled Trial.